Dr. Jay Lalezari, CEO and CMO of CytoDyn, discusses how Leronlimab’s unique CCR5-blocking mechanism has carried it from HIV, to Covid-19, to a promising, one-of-a-kind proof of concept in colorectal cancer.
Feature|Articles|August 13, 2026
- Pharmaceutical Executive: August 2026
- Volume 46
- Issue 6
2026 Emerging Pharma Leaders
Author(s)Mike Hollan
Listen
0:00 / 0:00
From guiding pursuits in artificial intelligence and R&D to scientific marketing and company building, meet Pharm Exec’s new slate of select rising leaders who are helping to shape the next generation of biopharma innovation.
Advertisement
Follow the links below to read about each selection:
(In alphabetical order)
* These five selections were chosen from a pool of nominations evaluated by the Pharmaceutical Executive Editorial staff. Selections were based on a number of criteria and review of professional accomplishments and progression of responsibilities in line with those executives inhabiting key “C-suite” functions.
Articles in this issue
3 months ago
More Than Titles3 months ago
2026 Pharm Exec Top 50 Companies3 months ago
Making the Smart Career Moves3 months ago
Finding the Universal Truth in a Drug's Story3 months ago
What C-Suite Readiness Really RequiresAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
How microgravity is opening new possibilities for drug R&D and manufacturing, a pharma funding roundup covers Boehringer Ingelheim’s up-to-$7 billion oncology licensing deal with Sino Biopharmaceutical and Nxera Pharma’s EP4 agonist deal with AbbVie, and CytoDyn’s Dr. Jay Lalezari on why Leronlimab isn’t just another repurposed drug.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Dr. Jay Lalezari, CytoDyn’s CEO and CMO, discusses his path from HIV clinician to drug developer.
Boehringer Ingelheim licenses six preclinical oncology programs from Sino Biopharmaceutical in a deal worth up to $7 billion, while Nxera Pharma licenses its EP4 agonist program for inflammatory bowel disease to AbbVie for up to $1.37 billion.
Advertisement
Advertisement
Trending on PharmExec
1
What Does a Positive Reading for Leronlimab Mean for How the Industry Thinks About Repurposing Old Biologics Into Oncology?
2
Lonza to Acquire Five U.S. CDMO Sites From Merck KGaA
3
Why Leronlimab Isn’t Just Another Repurposed Drug: Q&A with Dr. Jay Lalezari
4
How Tumors Change Over Time, and How This Impacts Treatment
5